Wrapping up the week that was for Australian shares, Beach Energy’s share price experienced the biggest growth on the ASX 200 amid a winning streak for commodities.
Shares in oil and gas company Beach Energy soared over 8% following the discovery of a new gas field in South Australia and strong oil prices.
Canstar general manager of wealth Josh Callaghan pointed to the performance of commodities as a standout in his read of the ASX’s performance last week.
“The resources sector continues its run in 2018 with Beach, South32 and BHP all getting a price boost from the shift in sentiment due to world markets,” he said.
CMC Markets chief market strategist Michael McCarthy said commodity markets are “painting a positive picture for shares” in Australia.
“Key industrial commodities such as oil, copper and iron ore are all at or near recent high points,” he said.
“This positive outlook reflects stronger China trade and US manufacturing reads.”
One electronics retailer is also recording a boom in share price following a strong Christmas trade period, with JB Hi-Fi’s shares hitting an 11-month high mid-last week.
Morgan Stanley analysts lifted their forecasts and growth outlook for the retailer, sighting strong performance driven by iPhone X, drone and TV sales.
Top 5 Winners and Losers of the ASX200 (08/01/2018 to 15/01/2018) | |||||
---|---|---|---|---|---|
Winners | Losers | ||||
Rank | Change (%) | Rank | Change (%) | ||
1 | Beach Energy (BPT) | 8.5 | 1 | Sigma Healthcare (SIG) | -11.9 |
2 | SOUTH32 (S32) | 7.6 | 2 | Blackmores (BKL) | -9.8 |
3 | JB Hi-Fi (JBH) | 7.4 | 3 | Australian Pharmaceutical Industries (API) | -7.7 |
4 | BHP Billiton (BHP) | 5.1 | 4 | Fisher & Paykel Healthcare (FPH) | -7.5 |
5 | Platinum Asset Management (PTM) | 5.0 | 5 | Macquarie Atlas Roads (MQA) | -7.3 |
Source: Canstar Research, January 15, 2018 Data source: Market Index |
Meanwhile, the stock prices of Sigma Healthcare (a pharmaceutical distributor) continue to dive, recording an 11.9% fall last week, with other health sector companies Blackmores, Australian Pharmaceutical Industries and Fisher & Paykel also experiencing significant dips.
“Sigma Health continues its rough start to the year and wiped out all of the gains of the Santa rally in the second half of December,” said Mr Callaghan.
“The market seems to be pushing it back towards the new average in the mid to late 80 cent mark since shocking the market in May with news of a lawsuit with key client My Chemist.”
Macquarie Atlas Roads also took a hit last week, likely driven by news it may have to start paying tax on its Dulles Greenway toll road in the United States after President Donald Trump passed changes to the US tax code in December.
Our Chief Economist Craig James shares his outlook for the sharemarket, #oil prices and the #AUD with the @ASX. Watch it here https://t.co/SbRim1cBgz #ausbiz #ausecon
— CommSec (@CommSec) January 15, 2018
Try our Online Share Trading comparison tool to instantly compare Canstar expert rated options.
This advice is general and has not taken into account your objectives, financial situation, or needs. It is not personal advice. Consider whether this advice is right for you, having regard to your own objectives, financial situation and needs. You may need financial advice from a suitably qualified adviser. For more information, read Canstar’s Financial Services and Credit Guide (FSCG) and our detailed disclosure. Canstar may receive a fee for referring you to a product provider – for further information, see how we get paid. Payment of fees for ads does not influence our Star Ratings or Awards.
Canstar is a comparison website, not a product issuer, so it’s important to check any product information directly with the provider. Consider the Product Disclosure Statement (PDS), Target Market Determination (TMD) and other applicable product documentation before making a decision to purchase, acquire, invest in or apply for a financial or credit product. Contact the product issuer directly for a copy of the PDS, TMD and other documentation.
Canstar is an information provider and in giving you product information Canstar is not making any suggestion or recommendation about a particular credit product or loan. If you decide to apply for a credit product or loan, you will deal directly with a credit provider, and not with Canstar. Rates and product information should be confirmed with the relevant credit provider. For more information, read the credit provider’s key facts sheet and other applicable loan documentation for that product. Read the Comparison Rate Warning.
The views, opinions, and positions expressed in this piece are the views of the author(s) alone, and do not necessarily reflect the views of Canstar.
All information about performance returns is historical. Past performance should not be relied upon as an indicator of future performance; unit prices and the value of your investment may fall or rise.
Canstar is an information provider and in giving you product information Canstar is not making any suggestion or recommendation about a particular product. The information has been prepared without taking into account your individual investment objectives, financial circumstances or needs. Before you decide whether or not to acquire a particular financial product you should assess whether it is appropriate for you in the light of your own personal circumstances, having regard to your own objectives, financial situation and needs. You may wish to obtain financial advice from a suitably qualified adviser before making any decision to acquire a financial product. Please refer to the product disclosure statement (PDS) and Canstar’s Financial Services and Credit Guide (FSCG) for more information, and read our detailed disclosure, important notes and liability disclaimer.
Any advice provided on this website is general and has not taken into account your objectives, financial situation or needs. Consider whether this advice is right for you. Consider the Product Disclosure Statement and Target Market Determination before making a purchase decision. Canstar provides an information service. It is not a credit provider, and in giving you information about credit products Canstar is not making any suggestion or recommendation to you about a particular credit product. Research provided by Canstar Research AFSL and Australian Credit Licence No. 437917. You must not reproduce, transmit, disseminate, sell, or publish information on this website without prior written permission from Canstar.